Gabapentin, an anticonvulsant and nerve ache treatment, shouldn’t be usually included in normal drug screenings. Routine urine drug assessments primarily detect substances like opioids, benzodiazepines, amphetamines, cocaine, and marijuana. The presence of gabapentin requires particular testing strategies past these normal panels.
The rare inclusion of gabapentin in drug screenings stems from its comparatively low potential for abuse in comparison with different managed substances. Testing for this treatment is normally solely carried out when there’s a particular scientific indication or suspicion of misuse, reminiscent of in instances of suspected drug diversion or in sufferers with a historical past of substance abuse. Its detection provides insights into treatment adherence or potential off-label use.